Company: PTPI
Filing Date: 2025-02-13
Form Type: S-1/A
Source: 0001410578-25-000122
Chunk: 24

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-02-13
Form: S-1/A
Chunk 24
---
 common stock underlying outstanding stock options of the Company, with a weighted average exercise price of $4.77 per share; |

| ● | 252,378 shares of common stock issuable upon conversion of the 567.85 shares of the Company’s Series A Convertible Preferred Stock (“Series A Preferred Stock”) outstanding, at a conversion price of $2.25 per share, which excludes any Make-Whole Amounts (as defined in the Certificate of Designations), any Additional Amounts (as defined in the Certificate of Designations), any Late Charges (as defined in the Certificate of Designations) and any accrued dividends thereon; |

| ● | 47,658 shares of common stock reserved for issuance under the Company’s Amended and Restated 2020 Omnibus Incentive Compensation Plan (as amended, the “Plan”); and |

| ● | 2,200,000 of restricted shares of common stock to be issued to certain directors and officers of the Company subject to the closing of this offering, pursuant to the Stock Awards. |

Except as otherwise indicated, all information in this prospectus assumes no exercise of the outstanding warrants, no conversion of Series A Preferred Stock, no shares of our common stock are issued pursuant to outstanding stock options and no shares of common stock are issued pursuant to our Plan described above. The discussion above assumes no exercise of Pre-Funded Warrants in this offering and excludes the shares of common stock issuable upon conversion of the Series B Preferred Stock that is issuable upon exercise of the Series Warrants to be issued in this offering.

11

<div align='center'>**Risk Factors**</div>

Investment in our securities, including our common stock, Series Warrants, and Pre-Funded Warrants, involves a high degree of risk. In addition to the risks and investment considerations discussed elsewhere in this prospectus, or any “free writing prospectus” we have authorized in connection with this offering, the following factors should be carefully considered by anyone purchasing the securities offered by this prospectus. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations. If any of the following risks actually occur, our business could be harmed. In such case, the trading price of our common stock could decline and investors could lose all or a part of their investment. All of these risks could adversely affect our business, business prospects, results of operations, financial condition and cash flows